Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

Stefan Winter,Pascale Fisel,Florian Büttner,Anne T. Nies,A. Stenzl,Jens Bedke,Matthias Schwab,Elke Schaeffeler

Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

2017

Stefan Winter
Pascale Fisel
Florian Büttner
Anne T. Nies
A. Stenzl
Jens Bedke
Matthias Schwab
Elke Schaeffeler

Although the combination of decitabine and platinum drugs may be promising for therapy of renal cell carcinoma, the role of OCT2 needs further investigations.

Keywords:

Drug
Decitabine
Pharmacology
Epigenetics
Oxaliplatin
Renal cell carcinoma
Biology
Diabetes mellitus
Epigenomics
drug transporter
Organoplatinum Compounds

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations